Chugai Pharmaceutical (OTCMKTS:CHGCY) Shares Gap Up – Should You Buy?

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) shares gapped up prior to trading on Wednesday . The stock had previously closed at $31.21, but opened at $33.2299. Chugai Pharmaceutical shares last traded at $31.49, with a volume of 32,836 shares trading hands.

Analyst Ratings Changes

A number of research firms have weighed in on CHGCY. Smbc Nikko Sec. raised shares of Chugai Pharmaceutical to a “strong-buy” rating in a report on Wednesday, February 25th. UBS Group raised shares of Chugai Pharmaceutical to a “strong-buy” rating in a research report on Tuesday, January 27th. Two investment analysts have rated the stock with a Strong Buy rating, Based on data from MarketBeat, Chugai Pharmaceutical currently has an average rating of “Strong Buy”.

Chugai Pharmaceutical Stock Down 3.1%

The company has a fifty day moving average price of $28.69 and a two-hundred day moving average price of $25.70. The firm has a market capitalization of $101.20 billion, a price-to-earnings ratio of 35.34 and a beta of 0.60.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last issued its quarterly earnings results on Thursday, January 29th. The company reported $0.25 earnings per share for the quarter. The firm had revenue of $2.25 billion during the quarter. Chugai Pharmaceutical had a net margin of 34.47% and a return on equity of 22.00%. On average, equities analysts anticipate that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.74 earnings per share for the current fiscal year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.